{"links":{"html":"https://www.erudio.com/reports/primordium-nct04557059","json":"https://www.erudio.com/reports/primordium-nct04557059.json","markdown":"https://www.erudio.com/reports/primordium-nct04557059.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"primordium-04557059"}},"request":"https://www.erudio.com/contact?report=primordium-04557059"},"offer":{"cited_commentary_sources":18,"verified_hcp_statements":312,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":1950,"identity_verified_people":32,"optional":true,"price_per_verified_person_usd":15,"price_usd":480,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":1950,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"primordium-nct04557059"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=primordium-04557059","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/primordium-nct04557059","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"deep","size_rule":"Deep: 301+ verified statements","updates_usd":{"3_months":3400,"6_months":4900,"12_months":6800},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-31T20:28:11.390558Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":13,"no_commentary_found":1},"aspects":[{"claim_count":3,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":3,"title":"Primary endpoint: Prostate specific Membrane Antigen-Positron Emission Tomography (PSMA-PET) Metastatic Progression-free Survival (ppMPFS)"},{"claim_count":0,"coverage":"no_commentary_found","id":"T2","registry_field":"outcomesModule.secondaryOutcomes","source_count":0,"title":"Secondary endpoints"},{"claim_count":8,"coverage":"discussed","id":"T3","registry_field":"conditionsModule","source_count":3,"title":"Population and setting"},{"claim_count":5,"coverage":"discussed","id":"T4","registry_field":"armsInterventionsModule.armGroups","source_count":2,"title":"The comparison"},{"claim_count":12,"coverage":"discussed","id":"T5","registry_field":"outcomesModule","source_count":4,"title":"Safety and tolerability"},{"claim_count":5,"coverage":"discussed","id":"T6","registry_field":"designModule","source_count":2,"title":"Design and conduct"},{"claim_count":15,"coverage":"discussed","id":"A1","source_count":3,"title":"Clinical meaning of progression delay and the added contribution of MDT"},{"claim_count":26,"coverage":"discussed","id":"A2","source_count":7,"title":"Finite duration, deferral and treatment cessation"},{"claim_count":12,"coverage":"discussed","id":"A3","source_count":2,"title":"Choice of systemic agent, selected monotherapy and disease-definition conditions"},{"claim_count":16,"coverage":"discussed","id":"A4","source_count":5,"title":"PET certainty, confirmatory work-up and access-dependent decisions"},{"claim_count":18,"coverage":"discussed","id":"A5","source_count":5,"title":"Clinical risk, genomic work-up and biomarker-guided selection"},{"claim_count":19,"coverage":"discussed","id":"A6","source_count":1,"title":"Radiotherapy fractionation, pelvic dose and late-toxicity evidence"},{"claim_count":25,"coverage":"discussed","id":"A7","source_count":1,"title":"ADT sequencing and disputed radiosensitization rationale"},{"claim_count":18,"coverage":"discussed","id":"A8","source_count":6,"title":"Shared decisions, supportive care and regional multidisciplinary infrastructure"}],"counts":{"cited_sources":18,"claims_by_expression_type":{"comparison":14,"experience":41,"interpretation":60,"opinion":85,"primary_context":1,"question":34,"restatement":25,"uncertainty":21,"unspecified":31},"claims_by_kind":{"interpretation":5,"source_observation":307},"clinician_statements":60,"evidence_units":261,"findings":11,"organisational_accounts":2,"people_cited":41,"people_identity_verified":32,"people_total":41,"screened_sources":30,"verified_claims":312},"findings_index":[{"id":"F1","structure":{"claims":13,"claims_by_group":{"comparisons":3,"experience":0,"questions":2,"restated":1,"views":7},"has_counterview":true,"limitations":2,"links":{"context":4,"support":13},"ma_question":true,"named_voices":3,"passages":8,"sources":3,"sources_by_kind":{"media":3}},"title":"Limited PSMA-only recurrence does not automatically justify lifelong systemic treatment"},{"id":"F2","structure":{"claims":18,"claims_by_group":{"comparisons":0,"experience":1,"questions":7,"restated":1,"views":9},"has_counterview":true,"limitations":5,"links":{"context":2,"support":19},"ma_question":true,"named_voices":10,"passages":20,"sources":3,"sources_by_kind":{"commentary":1,"media":2}},"title":"The debate turns on meaningful patient benefit, not progression delay alone"},{"id":"F3","structure":{"claims":18,"claims_by_group":{"comparisons":2,"experience":0,"questions":1,"restated":7,"views":8},"has_counterview":false,"limitations":4,"links":{"context":3,"support":20},"ma_question":true,"named_voices":8,"passages":16,"sources":12,"sources_by_kind":{"commentary":6,"media":6}},"title":"Interest in PRIMORDIUM is prospective and focused on its PSMA-defined question and endpoint"},{"id":"F4","structure":{"claims":14,"claims_by_group":{"comparisons":0,"experience":4,"questions":2,"restated":1,"views":7},"has_counterview":true,"limitations":3,"links":{"context":1,"support":15},"ma_question":true,"named_voices":3,"passages":8,"sources":3,"sources_by_kind":{"commentary":2,"media":1}},"title":"Reasons to defer systemic treatment remain part of the treatment decision"},{"id":"F5","structure":{"claims":12,"claims_by_group":{"comparisons":0,"experience":1,"questions":2,"restated":2,"views":7},"has_counterview":true,"limitations":3,"links":{"context":2,"support":15},"ma_question":true,"named_voices":3,"passages":10,"sources":2,"sources_by_kind":{"media":2}},"title":"Evidence-specific agent choice coexists with selective monotherapy and class-effect opinions"},{"id":"F6","structure":{"claims":16,"claims_by_group":{"comparisons":0,"experience":6,"questions":1,"restated":2,"views":7},"has_counterview":true,"limitations":4,"links":{"context":3,"support":19},"ma_question":true,"named_voices":8,"passages":18,"sources":5,"sources_by_kind":{"commentary":2,"media":3}},"title":"Imaging confidence and access determine whether clinicians act on PET findings"},{"id":"F7","structure":{"claims":17,"claims_by_group":{"comparisons":0,"experience":3,"questions":4,"restated":2,"views":8},"has_counterview":true,"limitations":3,"links":{"context":3,"support":18},"ma_question":true,"named_voices":5,"passages":18,"sources":5,"sources_by_kind":{"commentary":1,"media":4}},"title":"Risk and biology are proposed selectors, but prognostic information is not proof of treatment benefit"},{"id":"F8","structure":{"claims":23,"claims_by_group":{"comparisons":0,"experience":7,"questions":7,"restated":3,"views":6},"has_counterview":true,"limitations":3,"links":{"context":3,"support":24},"ma_question":true,"named_voices":14,"passages":23,"sources":1,"sources_by_kind":{"commentary":1}},"title":"Radiotherapy restrictions raise concerns about relevance, feasibility and unresolved late toxicity"},{"id":"F9","structure":{"claims":25,"claims_by_group":{"comparisons":1,"experience":1,"questions":7,"restated":1,"views":15},"has_counterview":true,"limitations":3,"links":{"context":0,"support":27},"ma_question":true,"named_voices":10,"passages":27,"sources":1,"sources_by_kind":{"commentary":1}},"title":"Very short ADT courses generate separate questions about timing, mechanism and actual benefit"},{"id":"F10","structure":{"claims":18,"claims_by_group":{"comparisons":0,"experience":7,"questions":2,"restated":1,"views":8},"has_counterview":true,"limitations":3,"links":{"context":1,"support":22},"ma_question":true,"named_voices":8,"passages":19,"sources":6,"sources_by_kind":{"commentary":1,"media":5}},"title":"Shared decisions require care coordination and support for treatment burden"},{"id":"F_context_nmHSPC_education","structure":{"claims":2,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":1,"views":1},"has_counterview":false,"limitations":4,"links":{"context":0,"support":2},"ma_question":true,"named_voices":1,"passages":2,"sources":1,"sources_by_kind":{"commentary":1}},"title":"Educational nmHSPC context: expected intensification benefit and PET-guided targeting"}],"medical_affairs_question":"What evidence would show that adding apalutamide improves outcomes meaningful to patients, while identifying who can safely avoid, shorten or stop systemic treatment?","sections":{"analysis":[{"id":"section-1","level":2,"title":"1. Disease classification changes treatment intent and duration"},{"id":"section-2","level":2,"title":"2. Added treatment must be judged against patient benefit, not only a later progression event"},{"id":"section-3","level":2,"title":"3. PRIMORDIUM attracts interest as an unanswered imaging-defined treatment question"},{"id":"section-4","level":2,"title":"4. Deferral has clinical reasons, preference conditions and research alternatives"},{"id":"section-5","level":2,"title":"5. Regimen selection is conditional on both the evidence and the imaging-defined setting"},{"id":"section-6","level":2,"title":"6. PET interpretation and access can change the decision before treatment is chosen"},{"id":"section-7","level":2,"title":"7. Biological selection is attractive, but prognosis and prediction must remain separate"},{"id":"section-8","level":2,"title":"8. Radiotherapy conduct must balance contemporary practice with toxicity uncertainty"},{"id":"section-9","level":2,"title":"9. One month of ADT is not settled by a radiosensitization argument"},{"id":"section-10","level":2,"title":"10. Treatment choices require support structures, not only regimen selection"},{"id":"section-11","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[{"id":"F3","shared_claims":3}],"id":"T1","label":"Primary endpoint: Prostate specific Membrane Antigen-Positron Emission Tomography (PSMA-PET) Metastatic Progression-free Survival (ppMPFS)"},{"findings":[],"id":"T2","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":7},{"id":"F3","shared_claims":1}],"id":"T3","label":"Population and setting"},{"findings":[{"id":"F3","shared_claims":3},{"id":"F4","shared_claims":2}],"id":"T4","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":3},{"id":"F3","shared_claims":1},{"id":"F5","shared_claims":1},{"id":"F8","shared_claims":5},{"id":"F9","shared_claims":1},{"id":"F10","shared_claims":1}],"id":"T5","label":"Safety and tolerability"},{"findings":[{"id":"F3","shared_claims":1},{"id":"F8","shared_claims":4}],"id":"T6","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-31T20:28:11.390558Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-31T20:41:35Z","record_hash":"b5daf24e20b1a6d16a155658cfb65cdee7489852486c11cc766f2396200a79c4","release_hash":"dc30b59923fa17f6bbc370f3ca284c2dc04469e8910f164707ca27f2052bf532","report_id":"erudio-nct04557059","run_id":"08cf2c8d-5d94-4a20-90f6-ca9659eb2455","schema_version":"5.0","slug":"primordium-04557059","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"PRIMORDIUM asks whether adding apalutamide to salvage radiotherapy and ADT delays metastatic progression in men with high-risk, PSMA-PET-positive hormone-sensitive prostate cancer recurrence. Commentary comes from X threads, podcasts and YouTube discussions, including contributions from a medical oncologist. The discussion turns on prospective interest in the PSMA-defined endpoint, whether progression delay delivers meaningful patient benefit, and how radiotherapy restrictions affect clinical relevance and feasibility amid unresolved late-toxicity questions.","meta_description":"30 sources screened · 312 verified statements (60 from clinicians verified by NPI or staff page) from 18 sources · 11 findings. Updated Oct 31, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-926f4c70fcfbbf6d49cc","claim-1dc218fbc041d50182dd"],"id":"F2","paraphrase":"An X exchange asks whether trials isolate SBRT's contribution using metastasis-free or overall survival endpoints, alongside questions about temporary ADT duration in salvage treatment. The duration discussion includes a contributor described in the source as involved in PRIMORDIUM.","publication_caveats":{"reason":"Publication caveats are not stated in the sources reviewed for this edition.","status":"not_set"},"source_channel":"x_thread","source_date":"2023-04-04","title":"The debate turns on meaningful patient benefit, not progression delay alone"},{"cited_claim_ids":["claim-46ed9c4fa265088bf506","claim-354f63ffc37780ca5407","claim-4e788f37e0e28e772204"],"id":"F8","paraphrase":"An X exchange linked conditionally to PRIMORDIUM asks about a sequential boost to the prostate bed and whether hypofractionation could affect very-late bladder toxicity.","publication_caveats":{"reason":"Publication caveats are not stated in the sources reviewed for this edition.","status":"not_set"},"source_channel":"x_thread","source_date":"2021-06-10","title":"Radiotherapy restrictions raise concerns about relevance, feasibility and unresolved late toxicity"}]},"publication":{"approved_at":"2026-10-31T20:41:35Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":30},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Not yet captured in this edition: a view on molecular subtype selection for adding hormonal therapy to salvage radiotherapy in recurrent prostate cancer.","Not yet captured in this edition: a view on unequal access to PSMA PET for initial staging versus monitoring.","Not yet captured in this edition: a view on how postoperative disease status qualifies adjuvant-versus-salvage radiotherapy comparisons.","Not yet captured in this edition: a view on age, chemotherapy fitness and PSA kinetics when selecting patients for treatment intensification.","Not yet captured in this edition: a view on community referral networks and regional limitations in access to multidisciplinary specialty care.","Not yet captured in this edition: a question about omitting ADT during early salvage radiotherapy and using genomic assays to guide selection.","Not yet captured in this edition: a question about counseling patients on localized prostate cancer and local treatment choices.","Not yet captured in this edition: a view on adopting recurrence-reducing treatment approaches conditional on positive study evidence.","Not yet captured in this edition: a view on androgen-receptor–targeted treatment intensification in biochemical recurrence.","Not yet captured in this edition: a view on uncertainty in imaging-defined disease status when choosing systemic or metastasis-directed treatment.","Not yet captured in this edition: a view on uncertain benefit from treatment intensification, pelvic-radiation subgroup interpretation, and incomplete publication in high-risk localized disease.","Not yet captured in this edition: a question about whether continuous versus intermittent androgen deprivation and androgen-receptor inhibition changes benefits in high-risk hormone-sensitive prostate cancer.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","455 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.","The sources reviewed for this edition do not include an available protocol or an exact-trial results publication; favorable reactions cannot establish PRIMORDIUM efficacy or safety.","Commentators give differing accounts of treatment duration and prior local treatment. These differences are preserved rather than resolved from incomplete documentation.","Discussion coverage is incomplete. Trial-name searches can miss unnamed references, and some relevant sections of longer programs were not fully assessed. The report therefore cannot fully characterize every treatment preference, reason for deferral, stopping strategy or comparative-endpoint interpretation expressed in those programs; absence here does not establish absence of dissent.","Podcast and video versions contain overlapping a speaker–another speaker material; their repetition is not additional independent HCP evidence.","Unknown speakers may be named participants in the same program and are not counted as separate people or placed in opposition to identified speakers from that program.","Other-study efficacy accounts, biological mechanisms, assay-approval statements and future implementation forecasts are attributed views, not independently adjudicated conclusions.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","Drug-label information available for this edition does not establish authorization for the particular trial combination.","Publication and post dates identify the source timing, not necessarily the date of the underlying session or a study readout; they do not establish changes of mind."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":7,"publication":0,"registry":0,"regulatory":0,"x_thread":9,"x_video":0,"youtube":2},"by_evidence_role":{"commentary":18},"count":18,"evidence_window":{"end":"2026-08-24","start":"2021-06-10"},"retrieval_snapshot":"2026-10-31T14:02:10.220541Z","timeline":[{"count":1,"week":"2021-W23"},{"count":2,"week":"2021-W39"},{"count":1,"week":"2021-W40"},{"count":1,"week":"2023-W14"},{"count":1,"week":"2023-W15"},{"count":1,"week":"2024-W13"},{"count":1,"week":"2024-W20"},{"count":1,"week":"2024-W22"},{"count":1,"week":"2024-W48"},{"count":1,"week":"2025-W07"},{"count":1,"week":"2025-W37"},{"count":1,"week":"2026-W08"},{"count":1,"week":"2026-W18"},{"count":1,"week":"2026-W20"},{"count":2,"week":"2026-W28"},{"count":1,"week":"2026-W33"},{"count":1,"week":"2026-W35"}],"undated_sources":0},"quote_policies":[{"id":"clinicaltrials:NCT04557059:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT04557059:context","quote_policy":"short_quote_link_out"},{"id":"openfda:d1cda4f7-cb33-46ea-b9ac-431f6452b1a5:20260702","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:11e0f5","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:4a0431","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:50100b","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:64e36b","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:7a8065","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:c38c40","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:e91200","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1402920846545596416:da99529b-12a8-49fc-bf80-fb8d9d8b85bb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1438940920037134336:96ffcd96-2beb-42cb-8e33-fea6cbec7b57","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1443558344145391617:ecf73e1d-bf82-4bc5-bdc7-254536492987","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1444299427456368645:ab420e0a-2c1d-4aa6-9f2c-4894405da6ad","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1445752544605601813:ad833662-9b6c-473e-b345-220985745498","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1542658379457253378:ed9f7866-0878-4d73-a920-2f1edf0a0b9e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1542695412053975040:ee88caf8-79c9-4d02-90d9-3c7802ee3847","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1643193920451641344:5d5beba0-df8d-40bf-99cb-50dd21aee046","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1703383913500967148:74b12c47-b5e2-4e26-b045-618c176a93f9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1703435984040341966:2edcbb2a-2daa-4b4d-a731-9e15fae61c68","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1758504207923999185:ee620e70-1f0b-4a2e-a04a-3862fe6700cc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1773107787087650883:aaea9868-31b5-4135-96a9-9c49b8429f6b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1781759776084361326:85216fc6-90af-4d2c-a706-fe461f36254c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1783464169775280305:3e0c3c64-2bfd-4183-bc7a-a3aea91232b6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1783471829455163464:a0dbda96-2b55-40a5-b494-4aebc9f19b94","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1790094703444025394:fe2cbc82-859b-4a6b-905d-51bc01293e1b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1801283478102647238:2eac6dd3-aa21-4799-908d-b4bf4ea9bbc6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1805900015518241025:b8562724-ebfc-4343-9776-01960d23c3f3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1814359617331175618:e2944aaf-07f1-4b26-88c1-100449e561e1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1862500987774132432:5169d79f-3d1a-4128-9a5b-cabbef89c5b5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2023419835145678946:d41235aa-d7f9-4ce5-b586-b53df5906fa5","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:Gbg_CWOyqtg","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:YzCLxqFhcWs","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":7,"publication":0,"registry":0,"regulatory":0,"x_thread":21,"x_video":0,"youtube":2},"by_evidence_role":{"commentary":30},"count":30,"evidence_window":{"end":"2026-08-24","start":"2021-06-10"},"retrieval_snapshot":"2026-10-31T14:02:10.220541Z","timeline":[{"count":1,"week":"2021-W23"},{"count":1,"week":"2021-W37"},{"count":2,"week":"2021-W39"},{"count":1,"week":"2021-W40"},{"count":2,"week":"2022-W26"},{"count":1,"week":"2023-W14"},{"count":1,"week":"2023-W15"},{"count":2,"week":"2023-W37"},{"count":1,"week":"2024-W07"},{"count":1,"week":"2024-W13"},{"count":1,"week":"2024-W16"},{"count":2,"week":"2024-W17"},{"count":1,"week":"2024-W20"},{"count":1,"week":"2024-W22"},{"count":1,"week":"2024-W24"},{"count":1,"week":"2024-W26"},{"count":1,"week":"2024-W29"},{"count":1,"week":"2024-W48"},{"count":1,"week":"2025-W07"},{"count":1,"week":"2025-W37"},{"count":1,"week":"2026-W08"},{"count":1,"week":"2026-W18"},{"count":1,"week":"2026-W20"},{"count":2,"week":"2026-W28"},{"count":1,"week":"2026-W33"},{"count":1,"week":"2026-W35"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: lhrha","status":"unmapped"},{"reason":"Unmapped registry intervention: apalutamide","status":"unmapped"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Prostate cancer","slug":"prostate-cancer"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"PRIMORDIUM","aliases":["PRIMORDIUM","A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer","A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer, Assessed by PSMA-PET With an Observational Cohort"],"brief_title":"A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Prostatic Neoplasms"],"display_condition":"high-risk hormone-sensitive prostate cancer","display_interventions":[["apalutamide"]],"enrollment":{"count":691,"type":"ACTUAL"},"interventions":[{"name":"Radiotherapy","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"RADIATION"},{"name":"LHRHa","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Apalutamide","synonyms":["JNJ-56021927"],"type":"DRUG"}],"nct_id":"NCT04557059","official_title":"A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer, Assessed by PSMA-PET With an Observational Cohort","overall_status":"ACTIVE_NOT_RECRUITING","phase":["PHASE3"],"primary_completion_date":{"date":"2029-08-27","type":"ESTIMATED"},"primary_endpoints":[{"description":"ppMPFS is defined as the appearance of at least one new PSMA-PET-positive distant lesion compared with the previous scan as assessed by blinded independent central review (BICR) or death.","measure":"Prostate specific Membrane Antigen-Positron Emission Tomography (PSMA-PET) Metastatic Progression-free Survival (ppMPFS)","timeFrame":"Up to 9 years"}],"registered_date":{"date":"2020-09-21","type":"ACTUAL"},"registry_last_updated":"2026-09-25","registry_url":"https://clinicaltrials.gov/study/NCT04557059","short_name":"PRIMORDIUM","short_name_basis":"registry_acronym","sponsor":"Janssen Pharmaceutica N.V., Belgium","start_date":{"date":"2020-11-12","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"CR108705","type":"sponsor_study_id"},{"domain":"Janssen Research & Development, LLC","id":"56021927PCR3015","type":"other"},{"id":"2019-002957-46","type":"eudract_number"},{"domain":"EUCT number","id":"2023-505852-23-00","type":"registry"}],"study_type":"INTERVENTIONAL"}}}